Page 8 - Emonstrate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Winnebago Industries Reports Third Quarter Fiscal 2023 Results

Diversified Outdoor Portfolio Continues to Demonstrate Resiliency and Strong Profitability Strong Cash Flow from Operations of $139.6 Million Completed Acquisition of Lithionics Battery,. | June 21, 2023

United statesDan sullivanRay posadasInnovation capabilities in diverse battery solutionsCompany fiscalWinnebago industries incExchange commissionYork stock exchangeNew york stock exchangeCompany board of directorsWinnebago industriesOutdoor portfolio continuesDemonstrate resiliencyCash flowLithionics batteryAccelerating innovation capabilities

Cobra Resources shares surge on rare earth intersection discovieries

Cobra Resources PLC on Tuesday said high-grade rare earth intersections at its Wudinna project demonstrate further rare earth element resource growth. Cobra Resources shares surged 21% to 1.39 pence. | June 20, 2023

South australiaHarvey dorsetRupert vercoCobra resourcesAustralia nuclear scienceTechnology organisationAlliance newsAlliance news ltdNuclear scienceExecutive rupert vercoWudinna projectAll rightsCobra resources plc stock exchangePress releaseO cobr gb00bgjw5255

Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases

Adagrasib is the first and only KRASG12C inhibitor to prospectively demonstrate intracranial activity in KRASG12C-mutated NSCLC with untreated CNS metastases Data demonstrate compelling. | June 20, 2023

Alan sandlerMirati therapeutics incPrnewswire mirati therapeutics incExchange commissionNational comprehensive cancer networkClinical practice guidelinesClinical oncologyMirati therapeuticsAccelerated approvalTime oncology reviewMarketing authorization applicationBreakthrough therapy designationPrescribing informationNc stock exchangePress releaseEmonstrate mrtx us60468t1051

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

Interim results demonstrate average reduction of 64% from baseline in serum NfL after 2 years of dosing with DNL310 in Phase 1/2 studyFDA has recommended assessment of NfL, a marker of neuroaxonal. | June 20, 2023

United statesJoseph muenzerLaura hansenHenrik zetterbergExchange commissionEuropean medicines agencyDrug administrationMedia relationsFast trackNorth americaSouth americaDenali hunterTransport vehicleSouth sanPrivate securities litigation reform actChief medical

The Estée Lauder Companies to Present Novel Scientific Data at World Congress of Dermatology

The Estée Lauder Companies to Present Novel Scientific Data at World Congress of Dermatology
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

United statesLe laboJaime emmetsbergerHao ouyangDanica chenKristine schmalenbergTom mammoneNadine pernodetClinical progress to promote skin healthNutritional sciences toxicologyUniversity of californiaNovel scientific data spanning emerging research areasResearch developmentLauder companiesLab seriesLauder companies inc